BDTX Black Diamond Therapeutics, Inc.: institutional ownership and insider trading
107 funds reported holding $71.5M of Black Diamond Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $1.75M, with 30 new positions and 31 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
Famous investors holding BDTX
- Renaissance Technologies (Renaissance Technologies): $3.63M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $291K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $279K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $77.7K, 0.0% of the portfolio
Largest institutional holders of BDTX
- NEA Management Company, LLC — $8.23M
- T. Rowe Price Investment Management, Inc. — $7.45M
- BlackRock, Inc. (BLK) — $7.25M
- VANGUARD GROUP INC — $5.32M
- ACADIAN ASSET MANAGEMENT LLC — $4.34M
- VANGUARD CAPITAL MANAGEMENT LLC — $3.93M
- RENAISSANCE TECHNOLOGIES LLC — $3.63M
- Defilade Capital Management, L.P. — $3.10M
- DIMENSIONAL FUND ADVISORS LP — $2.53M
- GEODE CAPITAL MANAGEMENT, LLC — $2.25M
Recent BDTX insider trades
- Mar 19, 2025: Biotech Growth N V sold 5,784,292 shares ($12.0M)
5%+ owners
- T. Rowe Price Investment Management, Inc.: 7.0% (Schedule 13G/A, filed Jul 8, 2026)
- BlackRock, Inc.: 6.7% (Schedule 13G, filed Jul 27, 2026)